ライフサイエンスコーパス: alanine transaminase

1 id not induce splenomegaly or increase serum alanine transaminase.

2 nd elevated plasma malondialdehyde (MDA) and alanine transaminase.

3 05, -0.02; P = 1.4 x 10(-6)) and with higher alanine transaminase (0.02 [0.01, 0.03]; P = 0.002) and

4 GPT2 [also known as alanine transaminase 2 (ALT2)] is one of two related tra

5 associated with higher circulating levels of alanine transaminase, a marker of liver injury, and with

6 lents per ml) and transiently elevated serum alanine transaminase activities were present from weeks

7 ied breads decreased triglyceride levels and alanine transaminase activity and caused an increase in

8 istry based on blood urea nitrogen levels or alanine transaminase activity--was observed in doses up

9 gamma-Glutamyl transpeptidase (28%) and alanine transaminase (ALT) (27%) were the most frequentl

10 apy, 8 of 19 (42%) patients had normal serum alanine transaminase (ALT) (complete responders).

11 e undergoing phlebotomy, we found that serum alanine transaminase (ALT) activities decreased but by l

12 tioxidant concentrations with abnormal serum alanine transaminase (ALT) activity in a large, national

13 Plasma alanine transaminase (ALT) activity, liver histology, an

14 l evaluable patients, accompanied by reduced alanine transaminase (ALT) activity.

15 re sensitivity to report liver injury versus alanine transaminase (ALT) and International Normalized

16 es mild steatosis, slight elevation of serum alanine transaminase (ALT) and little or no inflammation

17 Normalization of serum alanine transaminase (ALT) concentration (biochemical re

18 icacy was assessed by normalization of serum alanine transaminase (ALT) concentration and decrease in

19 rs (NRs) according to normalization of serum alanine transaminase (ALT) during treatment and follow-u

20 9 because of evidence of increased levels of alanine transaminase (ALT) in patients receiving the hig

21 or 9 weeks exacerbated an increase in plasma alanine transaminase (ALT) levels (227 +/- 75 vs. 140 +/

22 f hepatotoxicity as evidenced by lower serum alanine transaminase (ALT) levels (28 +/- 1 IU/L and 770

23 patients in the 10 MU group normalized serum alanine transaminase (ALT) levels and 59% had no hepatit

24 Elevated alanine transaminase (ALT) levels and low serum hepatiti

25 Serum alanine transaminase (ALT) levels are used to select hep

26 Elevated serum alanine transaminase (ALT) levels at 6 hours confirmed h

27 Ethanol increased serum alanine transaminase (ALT) levels from 30 +/- 6 to 64 +/

28 reased liver to body weight ratios and serum alanine transaminase (ALT) levels in AdlacZ-treated anim

29 CL (VE-CL, 1 mg/mouse) significantly lowered alanine transaminase (ALT) levels in CCl4-treated mice (

30 evels have been associated with raised serum alanine transaminase (ALT) levels in hepatitis C virus (

31 compared females versus males with elevated alanine transaminase (ALT) levels in the chronic HCV pat

32 reased liver-to-body weight ratios and serum alanine transaminase (ALT) levels in wild-type mice (109

33 Group B patients had lower mean serum alanine transaminase (ALT) levels than group A patients

34 Although a rise in alanine transaminase (ALT) levels was present at the tim

35 nol elevated liver:body weight ratios, serum alanine transaminase (ALT) levels, and pathology scores

36 ry endpoints included normalization of serum alanine transaminase (ALT) levels, disappearance of hepa

37 ly elevated aspartate transaminase (AST) and alanine transaminase (ALT) levels, indicative of severe

38 Serum alanine transaminase (ALT) levels, liver histology, hepa

39 y was defined by persistently elevated serum alanine transaminase (ALT) levels.

40 epatitis C virus (HCV) infection have normal alanine transaminase (ALT) levels.

41 stratification based on 2 consecutive serum alanine transaminase (ALT) levels.

42 shed neither I/R-induced elevations in serum alanine transaminase (ALT) nor AP-1 activation.

43 CBT protocol did not predict the peak serum alanine transaminase (ALT) observed in the patients.

44 The liver enzymes, alanine transaminase (ALT) or aspartate transaminase (AS

45 36, P =.0001) and negatively correlated with alanine transaminase (ALT) values (-0.178, P =.0001), du

46 study included 24 patients with normal serum alanine transaminase (ALT) values before therapy who had

47 virological complete responders had elevated alanine transaminase (ALT) values.

48 Median peak serum alanine transaminase (ALT) was 1,640 U/L (698-2,565 U/L)

49 ipoprotein (LDL) cholesterol, triglycerides, alanine transaminase (ALT), and aspartate transaminase (

50 n mean serum levels of alkaline phosphatase, alanine transaminase (ALT), and gamma-glutamyl transpept

51 h Study, for whom levels of plasma fetuin-A, alanine transaminase (ALT), and gamma-glutamyltranspepti

52 on) as well as aspartate transaminase (AST), alanine transaminase (ALT), and lactic dehydrogenase (LD

53 as reflected in phospho-c-jun levels, serum alanine transaminase (ALT), and liver histology were ass

54 atched with respect to age, sex, race, serum alanine transaminase (ALT), and liver histology.

55 patitis was associated with lower peak serum alanine transaminase (ALT), aspartate transaminase, and

56 Monitoring of alanine transaminase (ALT), creatinine, and full blood c

57 eflected by gamma-glutamyltransferase (GGT), alanine transaminase (ALT), fetuin-A, and the algorithm-

58 d for natural log (ln)-transformed values of alanine transaminase (ALT), gamma-glutamyltransferase (G

59 iver damage by alcohol was worse with higher alanine transaminase (ALT), more immune cell infiltratio

60 enzymatic assay targets alanine and employs alanine transaminase (ALT), pyruvate oxidase (POx), and

61 CP, rheumatoid factor (RF) titer, and serum alanine transaminase (ALT).

62 s, 1 with elevated and the other with normal alanine transaminase (ALT).

63 ields [HPF]) and severe liver injury (plasma alanine transaminase [ALT] activities: 4,120 +/- 960 U/L

64 ansaminase (aspartate transaminase [AST] and alanine transaminase [ALT]) and prothrombin time (PT) va

65 were measured and compared with biochemical (alanine transaminase [ALT]) and viral (HCV RNA) indicato

66 tantial necrosis (38% +/- 3% of hepatocytes; alanine transaminase [ALT]: 1,500 +/- 300 U/L) at 7 hour

67 = 2 x 10(-10)) was associated with levels of alanine transaminase, an indicator of liver damage.

68 an +/- standard deviation (SD) decreases for alanine transaminase and aspartate aminotransferase at w

69 e DMN-induced changes in the serum levels of alanine transaminase and aspartate transaminase (p<0.05)

70 Alanine transaminase and aspartate transaminase levels f

71 ubjects, and a reversible increase in plasma alanine transaminase and aspartic transaminase levels in

72 Higher levels of alanine transaminase and interleukin 10 were also associ

73 parallel with the hepatocyte marker enzymes alanine transaminase and lactate dehydrogenase.

74 entified dadRAX locus encoding the regulator alanine transaminase and racemase coupled with SpuC, the

75 gastroduodenal ulcers and elevated levels of alanine transaminase and total bilirubin in patients rec

76 osis, triglycerides, aspartate transaminase, alanine transaminase, and stellate cell proliferation by

77 trogen) and hepatic (aspartate transaminase, alanine transaminase, and total bilirubin) function in 3

78 nd had reduced serum levels of IFN-gamma and alanine transaminase as well as decreased expression of

79 ) and liver toxicity (proportion of patients alanine transaminase, aspartate aminotransferase and Alk

80 stay, and evaluation of serum transaminases (alanine transaminase, aspartate aminotransferase) and co

81 ls of serum bilirubin, alkaline phosphatase, alanine transaminase, aspartate transaminase, and bile a

82 like total leucocyte count, urea, bilirubin, alanine transaminase, aspartate transaminase, internatio

83 Elevated alanine transaminase/aspartate transaminase was seen in

84 llitus (P =.009), and aspartate transaminase/alanine transaminase (AST/ALT) ratio greater than 1 (P =

85 Serum levels of aspartate and alanine transaminases (AST and ALT) were mildly elevated

86 tosis (beta = 0.021; P = 3 x 10(-4)), higher alanine transaminase (beta = 0.002; P = 3 x 10(-5)), low

87 Alanine transaminase, bilirubin, and survival were deter

88 the serum levels of aspartate transaminase, alanine transaminase, blood urea nitrogen, and creatinin

89 chest x-ray findings, PaO2/FiO2, creatinine, alanine transaminase, cancer, cardiac arrest, chronic he

90 discontinued because of grade 3 or 4 raised alanine transaminase concentrations in 19 of 662 individ

91 LT, the mean peak aspartate transaminase and alanine transaminase concentrations in group A (1, 444.1

92 The duration of follow-up and serum alanine transaminase correlated with liver stiffness, an

93 -C), and hepatic (aspartate transaminase and alanine transaminase) damage and of decongestion (N-term

94 ild, transient events were tachycardia in 1, alanine transaminase elevation in 1, and hyperglycemia i

95 tudy was extended to monitor the activity of alanine transaminase enzyme, a key biomarker for the det

96 reater inflammatory cell infiltration, serum alanine transaminase, expression of hepatic inflammatory

97 The mitochondrial alanine transaminase GPT2 was found to be necessary and

98 ither a hepatic safety event (an increase in alanine transaminase >3 times the upper limit of normal

99 TRA and arsenic trioxide group, raised liver alanine transaminase in 11 (10%) of 108 versus 27 (25%)

100 y as manifested by increased blood levels of alanine transaminase in common for most of the eight com

101 were decreases in aspartate transaminase and alanine transaminase in the above-normal groups from 121

102 events occurred in 84% of neutropenia (32%), alanine transaminase increase (20%), aspartate transamin

103 kinase increase (30 [12%] vs one [<1%]), and alanine transaminase increase (28 [11%] vs 15 [6%]).

104 After 42 hr, alanine transaminase increased eightfold after RSLT and

105 nd NIM811, diminished the elevation of serum alanine transaminase level after I/R injury (174.0+/-28.

106 No consistent relationship between alanine transaminase level and TTV DNA level was observe

107 to spleen density of 1.0 or less, (2) serum alanine transaminase level greater than 30 U/L, and (3)

108 30 U/L, and (3) serum aspartate transaminase/alanine transaminase level less than 1.0.

109 ically significant (>/=grade 3) increases in alanine transaminase level or decreases in neutrophil co

110 ex situ perfusion, at which point perfusate alanine transaminase level was 1152 IU/L and urea concen

111 ad been hospitalized for 9 days; predonation alanine transaminase level was 63 IU/L, and the period f

112 ence of diabetes and hypertension, and lower alanine transaminase levels (P < .001 for all).

113 FN-gamma secreting and which correlated with alanine transaminase levels (r2 = 0.45; P = .001), were

114 ptible to AILI, as indicated by higher serum alanine transaminase levels and mortality.

115 enome equivalents per ml) for >2 years, with alanine transaminase levels becoming elevated again befo

116 ation disease, which is defined by a rise in alanine transaminase levels during ART.

117 as associated with stable or declining serum alanine transaminase levels in 4 patients.

118 titis in tamarins characterized by increased alanine transaminase levels that quickly return to norma

119 Serum alanine transaminase levels were increased in all BDL mi

120 Alanine transaminase levels were significantly elevated

121 Markers of liver injury, including serum alanine transaminase levels, apoptosis, hepatic fat load

122 The serum alanine transaminase levels, terminal deoxynucleotidyl t

123 al load (median 11-25 IU/ml) and have normal alanine transaminase levels.

124 r graft failure included log creatinine, log alanine transaminase, log aspartate transaminase, UNOS s

125 posure, hepatic oxidative insult, nor plasma alanine transaminase marking hepatocyte damage.

126 ory infection (20/0), pneumonia (13/10), and alanine transaminase or aspartate transaminase elevation

127 erence in incidence rates for an increase in alanine transaminase or total bilirubin between both CSL

128 dels, SF was associated with LIC (P = .006), alanine transaminase (P = .025), and weight (P = .026).

129 y to have higher body mass index (P = 0.04), alanine transaminase (P = 0.0001), alkaline phosphatase

130 specimens collected within 2 weeks after the alanine transaminase peak, at the end of the original st

131 Compared with WT, JNK2 KO mice had 38% less alanine transaminase release and 39% less necrosis by hi

132 1 +/- 36, PUGNAc: 42 +/- 22 pg/mL, p < .05), alanine transaminase (sham surgery: 95 +/- 14, control:

133 LP), leukogram, and dosages of aspartate and alanine transaminases, urea, and creatinine.

134 ntent correlated with waist-to-height ratio, alanine transaminase, uric acid, serum triglycerides, an

135 e hepatic enzymes aspartate transaminase and alanine transaminase were significantly greater in patie

136 r BMI, waist circumference, waist-hip ratio, alanine transaminase, white blood cell count and lower h